Relatório Público Europeu de Avaliação de Medicamentos para Uso Humano (EPAR): Mulpleo (anteriormente Lusutrombopag Shionogi), lusutrombopag, Data de autorização: 18/02/2019, Revisão: 9, Status: Retirado
On 14 April 2026, the European Commission withdrew the marketing authorisation for Mulpleo (lusutrombopag) in the European Union (EU).
Conteudo completo do artigo
On 14 April 2026, the European Commission withdrew the marketing authorisation for Mulpleo (lusutrombopag) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Shionogi B. V. , which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Mulpleo was granted marketing authorisation in the EU on 18 February 2019 to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2023. News on Mulpleo (previously Lusutrombopag Shionogi) Application under evaluation European Commission decision Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures This medicine's authorisation has been withdrawn This medicine’s product information is available in all official EU languages. Select 'available languages' to access the language you need. Product information documents contain: English (EN) (95.09 KB – PDF) English (EN) (83.73 KB – PDF) English (EN) (648.96 KB – PDF) summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA); conditions of the marketing authorisation (annex IIB);
package leaflet (annex IIIB). English (EN) (26.9 KB – PDF) Herengracht 4641017 CAAmsterdamThe Netherlands Mulpleo: EPAR – Medicine overview Lusutrombopag Shionogi: EPAR – Risk-management-plan summary Mulpleo: EPAR – Product information Mulpleo (previously Lusutrombopag Shionogi): EPAR – All authorised presentations български (BG) (125.14 KB – PDF) español (ES) (93.83 KB – PDF) čeština (CS) (118.08 KB – PDF) Deutsch (DE) (94.28 KB – PDF) ελληνικά (EL) (131.96 KB – PDF) français (FR) (94.17 KB – PDF) hrvatski (HR) (113.83 KB – PDF) italiano (IT) (92.96 KB – PDF) latviešu (LV) (119.27 KB – PDF) lietuvių (LT) (117.04 KB – PDF)
Produtos relacionados com este artigo
Estes produtos foram associados automaticamente a partir do titulo, resumo e conteudo do artigo.
Perguntas frequentes
Which products are related to this article?
The system matched these relevant products from the article content: Lusutrombopag – Compre online LUTRODX Lusutrombopag.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.